Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb Presents Sotyktu Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos in Symptomatic Obstructive Hypertrophic Cardiomyopathy at the European Society of Cardiology Congress 2026
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for Patients with Multiple Myeloma, as Early as First Relapse
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
Sankamap Expands Exploration Footprint at Fauro as Systematic Prospecting Advances and New Gold Targets Emerge
NevGold Defines Multiple High-Priority Drill Targets Including Key Feeder Structures at Nutmeg Mountain Gold Project, Idaho
Brixton Drills 58 m of 0.50 g/t AuEq and 17.6 m of 1.47 g/t AuEq in the Glenfiddich Zone at Camp Creek, Thorn Project
SAGA Metals Advances Radar Project to Stage 2 RCL Optimization Targeting First High-Purity Titanium, Vanadium and Iron Products
